The supplements are geared to the middle-age population struggling with weight and blood sugar control.
Life Extension has launched a new line of dietary supplements, comprising three products, geared to the middle-age population struggling with weight and blood sugar control. The line features Pharmachem Laboratories’ (Kearny, NJ) Phase 2 Carb Controller and Phase 3 Sugar Controller ingredients.
Phase 2 Carb Controller is a white kidney bean extract that inhibits the amylase enzyme in the digestive tract. (Amylase breaks down carbohydrates that are then absorbed into the bloodstream as glucose.) In several placebo-controlled trials, Phase 2 reduced starch digestion and resulted in weight loss. The ingredient is included in Life Extension’s new Calorie Control Weight Management Formula.
Phase 3 Sugar Controller is a patented L-arabinose compound that adjusts sucrase. It is part of Life Extension’s Optimized Irvingia with Phase 3 Sugar Controller product, which is designed to provide support to reverse the age-related metabolic changes that “predispose middle-aged individuals to weight gain, even when they cut back on caloric intake.”
The final new Life Extension product is Natural Glucose Absorption Control to support healthy postprandial glucose management. It features Pharmachem’s Phase 3 Sugar controller.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
Published: May 14th 2024 | Updated: May 15th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.